Immunohistochemical evaluation of p53 oncoprotein in transitional cell carcinoma of the upper urinary tract

Human Pathology

Volumn 27, Issue 12, 1996, Pages 1336-1340

  Nakanishi, Kuniaki ^a   Kawai, Toshiaki ^b   Torikata, Chikao ^b  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b NONE

Author keywords

p53 oncoprotein; transitional cell carcinoma; upper urinary tract

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER GROWTH; CANCER STAGING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; NEPHROURETERECTOMY; PROGNOSIS; STATISTICAL ANALYSIS; SURVIVAL RATE; TRANSITIONAL CELL CARCINOMA; TUMOR CLASSIFICATION; URINARY TRACT;

EID: 0029807571     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(96)90347-0     Document Type: Article

References (32)

1. Hollstein M, Sidransky D, Vogelstein B, et al: p53 mutations in human cancers. Science 253:49-53, 1991
2. Rodrigues NR, Rowan A, Smith MEF, et al: p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A 87:7555-7559, 1990
3. Bruner JM, Connelly JH, Saya H: p53 protein immunostaining in routinely processed paraffin-embedded sections. Mod Pathol 6:189-194, 1993
4. Finlay CA, Hinds PW, Tan T-H, et al: Activating mutations for transformation by p53 produce a gene product that forms an hsp70-p53 complex with an altered half-life. Mol Cell Biol 8:531-539, 1988
5. Sidransky D, Von Eschenbach A, Tsai Y, et al: Identification of p53 gene mutations in bladder cancer and urine samples. Science 252:706-709, 1991
6. Fujimoto K, Yamada Y, Okajima E, et al: Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 52:1393-1398, 1992
7. Dalbagni G, Presti JC, Reuter VE, et al: Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladder cancer. Diagn Mol Pathol 2:4-13, 1993
8. Wright C, Mellon K, Johnston P, et al: Expression of p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br J Cancer 63:967-970, 1991
9. Lipponen PK: Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int J Cancer 53:365-370, 1993
10. Sarkis AS, Dalbagni G, Cordon-Cardo C, et al: Nuclear overexpression of p53 protein in transitional cell carcinoma: A marker for disease progression. J Natl Cancer Inst 85:53-59, 1993
11. Esrig D, Spruck CH, Nichols PW, et al: p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 143:1389-1397, 1993
12. Fosså SD, Berner AA, Jacobsen A-B, et al: Clinical significance of DNA ploidy and S-phase fraction and their relation to p53 protein, c-ereB-2 protein and HCG in operable muscle-invasive bladder cancer. Br J Cancer 68:572-578, 1993
13. Soini Y, Turpeenniemi-Hujanen T, Kamel D, et al: p53 immunohistochemistry in transitional cell carcinoma and dysplasia of the urinary bladder correlates with disease progression. Br J Cancer 68:1029-1035, 1993
14. Furihata M, Inoue K, Ohtsuki Y, et al: High-risk human papillomavirus infections and overexpression of p53 protein as prognostic indicators in transitional cell carcinoma of the urinary bladder. Cancer Res 53:4823-4827, 1993
15. Thor AD, Moore DII, Edgerton SM, et al: Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845-855, 1992
16. Visakorpi T, Kallioniemi O-P, Heikkinen A, et al: Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 84:883-887, 1992
17. Scott N, Sagar P, Stewart J, et al: p53 in colorectal cancer: Clinicopathological correlation and prognostic significance. Br J Cancer 63:317-319, 1991
18. Oka K, Nakano T, Arai T: p53 CM1 expression is not associated with prognosis in uterine cervical carcinoma. Cancer 72:160-163, 1993
19. Purdie CA, O'Grady J, Piris J, et al: p53 Expression in colorectal tumors. Am J Pathol 138:807-813, 1991
20. Porter PL, Gown AM, Kramp SG, et al: Widespread p53 overexpression in human malignant tumors: An immunohistochemical study using methacarn-fixed, embedded tissue. Am J Pathol 140:145-153, 1992
21. Shurbani MS, Kalbfleisch JH, Thurmond TS: Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. HUM PATHOL 26:106-109, 1995
22. Huben RP, Mounzer AM, Murphy GP: Tumor grade and stage as prognostic variables in upper tract urothelial tumors. Cancer 62:2016-2020, 1988
23. Batata M, Grabstald H: Upper urinary tract urothelial tumors. Urol Clin North Am 3:79-86, 1976
24. Murphy DM, Zincke H, Furlow WL: Management of high grade transitional cell cancer of the upper urinary tract. J Urol 125:25-29, 1981
25. Akaza H, Koiso K, Niijima T: Clinical evaluation of urothelial tumors of the renal pelvis and ureter based on a new classification system. Cancer 59:1369-1375, 1987
26. Das AK, Carson CC, Bolick D, et al: Primary carcinoma of the upper urinary tract: Effect of primary and secondary therapy on survival. Cancer 66:1919-1923, 1990
27. Corrado F, Ferri C, Mannini D, et al: Transitional cell carcinoma of the upper urinary tract: Evaluation of prognostic factors by histopathology and flow cytometric analysis. J Urol 145:1159-1163, 1991
28. Al-Abadi H, Nagel R: Transitional cell carcinoma of the renal pelvis and ureter: Prognostic relevance of nuclear deoxyribonucleic acid ploidy studied by slide cytometry: An 8-year survival time study. J Urol 148:31-37, 1992
29. UICC (International Union Against Cancer): Renal pelvis and ureter, in Spiessl B, Beahrs OH, Hermanek P, et al (eds): Illustrated Guide to the TNM/pTNM Classification of Malignant Tumours (ed 3, 2nd rev). New York, NY, Springer-Verlag, 1992, pp 270-273
30. Murphy WM, Beckwith JB, Farrow GM: Tumors of the kidney, bladder, and related urinary structures, in Atlas of Tumor Pathology (3rd series, fasc. 11). Washington, DC, Armed Forces Institute of Pathology, 1994, pp 202-219
31. Iwaya K, Tsuda H, Fujita S, et al: Natural state of mutant p53 protein and heat shock protein 70 in breast cancer tissues. Lab Invest 72:707-714, 1995
32. SAS technical report P-217, SAS/STAT software: The PHREG Procedure (version 6). Cary, NC, SAS Institute Inc, 1991, p63